991
Participants
Start Date
December 17, 2015
Primary Completion Date
December 31, 2020
Study Completion Date
December 31, 2020
No Intervention
Participants who have a confirmed diagnosis of Psoriatic Arthritis (PsA) and are starting ustekinumab or a tumor necrosis factor alpha inhibitor (TNFi) as a first, second, or third line of biological disease-modifying antirheumatic drugs (bDMARD) therapy will be observed.
Brussels
Céroux-Mousty
Forest
Genk
Gilly
Hasselt
Leuven
Liège
Merksem
Besançon
Bordeaux
Clermont-Ferrand
Corbeil
Créteil
Lille
Lyon
Marseille
Montpellier, Herault
Paris
Toulouse
Tours
Athens
Heraklion
Larissa
Pátrai
Thessaloniki
Voula Attica
Alkmaar
Amsterdam
Den Helder
Groningen
Rotterdam
Sneek
Utrecht
Kemerovo
Khabarovsk
Moscow
Saint Petersburg
Saransk
Stavropol
Barcelona
Bilbao
Donostia / San Sebastian
Getafe
Granada
Madrid
Mérida
Salamanca
Valladolid
Vitoria-Gasteiz
Abergavenny
Bath
Cambridge
Cannock
Christchurch
Glasgow
Leeds
London
Manchester
Metropolitan Borough of Wirral
Reading
Salford
Sheffield
Stoke-on-Trent
Wigan
Wolverhampton
Janssen Pharmaceutica N.V., Belgium
INDUSTRY